First bioactive Sclerostin ELISA for clinical samples
19 March, 2019
The only Sclerostin ELISA that utilizes specific EPITOPE MAPPED ANTIBODIES enabling the analysis of bioactive Sclerostin in clinical samples
Assay Highlights:
- HIGHLY SPECIFIC and DEFINED: capture antibody directed against Sclerostin’s bioactive site
- RELIABLE: human serum based calibrators and controls, rigorously validated
- LOW SAMPLE VOLUME: 20 µl / well
- QUICK: total incubation time 3.5 h
Areas of interest: osteoporosis, cancer induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney diseases, therapy monitoring of anabolic treatment
For detailed information please click corresponding links:
BI-20472 bioactive Sclerostin product website
BI-20472 bioactive Sclerostin ELISA IFU
BI-20472 bioactive Sclerostin ELISA Validation Data
BI-20472 bioactive Sclerostin ELISA MSDS
Biomedica ELISA Service Quotation Forma
Share: